A story on how group insurers can help plan sponsors provide adequate coverage and ensure appropriate use of treatments for rare diseases was the most-read article on BenefitsCanada.com this past week. Here are the top five human resources, benefits, pension and investment stories of the last week: 1. Sounding Board: How employers can mitigate cost of […]
The World Health Organization defines a rare disease as having a prevalence of 65 or less per 100,000 individuals. It recognizes some 5,500 rare diseases, the majority being of genetic origin and often life-threatening. Medical research has yielded significant drug development for the treatment of rare diseases, increasing life expectancy and improving quality of life. However, […]
While the concept behind the federal government’s universal pharmacare plan is well intentioned, the program would make a larger impact for employers by focusing on high-cost and specialty drugs, says Pam Martin, vice-president and senior consultant at Baynes & White Inc. In theory, the way that the government is rolling out the program in small […]
An article on the Canadian Life and Health Insurance Association’s priorities for the coming year was the most-read story on BenefitsCanada.com this past week. Here are the top five human resources, benefits, pension and investment stories of the week: 1. CLHIA focusing on improving pharmacare, rare disease drug coverage in 2024 2. Majority of Canadian employers expecting […]
In the year ahead, the Canadian Life and Health Insurance Association will continue its advocacy efforts to ensure the federal government’s proposed pharmacare plan extends coverage for those who lack benefits without disrupting workplace benefits that millions of working Canadians rely on, says Stephen Frank, the association’s president and chief executive officer. The right approach to […]
A recent survey by Innovative Medicines Canada found there are growing listing delays among Canada’s private drug plans, said Joe Farago, the organization’s executive director of private payers and investment, during a session at Benefits Canada’s 2023 Face to Face Drug Plan Management Forum in December. The survey noted private payer review times can take […]
Many plan members with diabetes struggle with adherence to daily insulin injections and research has found the majority of patients wish they could achieve the same control over their condition with fewer injections, said Jacob Bonafiglia, medical science liaison with Novo Nordisk Canada Inc., during a panel discussion sponsored by Boehringer-Ingelheim Canada, Merck Canada Inc. […]
Pharmacists are now uniquely positioned to support Canadians at a time when the public health-care system is stretched thin, creating significant barriers for people looking to access care, said Dr. Jennifer Poh, senior director of drug plan solutions at Health Solutions by Shoppers, during Benefits Canada’s 2023 Face to Face Drug Plan Management Forum in […]
It’s important for private payers and employers to be nimble and innovative to support plan members seeking access to novel drugs and treatments by addressing common hurdles within their own drug plans, said John Adams, chair of the board of directors for patient advocacy group Best Medicines Coalition, during a session at Benefits Canada’s 2023 Face […]
A story on mental-health themes and challenges for 2024 was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Expert panel: Employers taking preventative, holistic approach to employee mental health in 2024 2. AI holds uncapped potential for pension plan sponsors’ administration, communications: […]